USP8, USP48, BRAF and TP53 mutations in crooke cell adenoma
Authors' conclusion
CCAs have slightly distinct mutational profile then other histological subtypes of cPAs. Since clinical relevance of TP53 variants in corticotroph tumors was already documented, testing toward TP53 sequence changes in patients with CCAs should be considered.
Study context
- Population
- Patients with Crooke cell adenoma (CCA), a rare histological subtype of corticotroph pituitary adenoma; FFPE tissue
- Participants
- 29 crooke cell adenomas (CCAs)
- Exposure
- Clinically functioning vs Nonfunctioning
- Clinically functioningn = 14
- Nonfunctioningn = 15
- Outcome
- Prevalence of USP8, USP48, BRAF and TP53 variants
Methodological detailsSanger sequencing, semiconductor sequencing (Ion AmpliSeq TP53 Panel)
- Sanger sequencing
- Semiconductor sequencing (Ion AmpliSeq TP53 Panel)
Main finding
As reported in the abstract
Prevalence of USP8, USP48, BRAF and TP53 variants in CCAs
- USP8 variants in CCA patients with Cushing's disease (CD)
- 2
- TP53 variants (1 CCA patient with CD, 2 with clinically nonfunctioning CCAs)
- 3
- BRAF V600E variant
- One
Observational data: associations, not effects.
Original publication
USP8, USP48, BRAF and TP53 mutations in crooke cell adenoma. Pituitary. Published 5 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →